We do the research together
Open positions available! Contact us for more information.
Prof. Dr. med. Jan-Henning Klusmann
Jan-Henning is an ERC grant-holder, Professor, and Director of Pediatrics & Pediatric Oncology at the University Hospital of Halle.
Prof. Dr. rer. nat. Dirk Heckl
Dirk is a Max Eder Fellow and Professor at the University Hospital of Halle. He specializes in CRISPR-Cas9 systems and modeling leukemia in mice.
PD. Dr. med. Jessica Höll
Jessica is a physician and junior group leader at the University Hospital of Halle. Her research centers on the role of RNA-binding proteins in leukemia.
Dr. Raj Bhayadia
Raj (postdoctoral fellow) works on patient-dervied xenograft models of pediatric AML, in vivo non-coding RNA studies, and pre-clinical drug testing.
Dr. Daniela Bräuer-Hartmann
Daniela (postdoctoral fellow) works on mapping the interactomes of the GATA1 / GATA1s transcription factors.
Dr. Hasan Issa
Hasan (postdoctoral fellow) works on delivering lipid nanoparticle-based oligonucleotides into AML cells, towards RNA-centered therapies.
Oriol Alejo
Oriol (PhD student, independent) is investigating the interactive genetic network of the stem cell microRNA cluster miR-99a/105~125b.
Michelle Ng
Michelle (PhD student, HBRS Molecular Medicine) is using a CRISPR interference-based screening platform to investigate long non-coding RNAs in AML.
Lonneke Verboon
Lonneke (PhD student, independent) is investigating interactions within the DLK1-DIO3 non-coding RNA locus in normal and malignant megakaryopoiesis.
Sofia Gialesaki
Sofia (PhD student, HBRS Molecular Medicine) is studying the interplay between chromosome 21 genes and GATA1s in Down syndrome AML.
Dorit Schneider
Dorit (PhD student, HBRS Molecular Medicine) is studying the deregulated network in Ezh2-mutated AML using state-of-the-art CRISPR-Cas9 technology.
Lucie Gack
Lucie (technician) supports the in vitro aspect of all non-coding RNA projects.
Alumni
Maurice Labuhn
Maurice (PhD student, HBRS Molecular Medicine) is using a lentiviral CRISPR-Cas9 system to model Down syndrome AML in vivo and in vitro.
David Mir-Salim
David (medical student, UKH) is performing drug testing on patient-dervied xenografts in vivo to find new potential therapies for childhood AML.